Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,128,096
  • Shares Outstanding, K 2,027,395
  • Annual Sales, $ 45,006 M
  • Annual Income, $ 8,025 M
  • EBIT $ 2,888 M
  • EBITDA $ 12,648 M
  • 60-Month Beta 0.44
  • Price/Sales 2.51
  • Price/Cash Flow 4.48
  • Price/Book 6.62

Options Overview Details

View History
  • Implied Volatility 25.93% ( -0.86%)
  • Historical Volatility 26.03%
  • IV Percentile 46%
  • IV Rank 38.37%
  • IV High 36.85% on 07/11/24
  • IV Low 19.14% on 11/06/23
  • Put/Call Vol Ratio 0.64
  • Today's Volume 16,068
  • Volume Avg (30-Day) 24,838
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 700,180
  • Open Int (30-Day) 721,437

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.53
  • Number of Estimates 10
  • High Estimate 1.61
  • Low Estimate 1.44
  • Prior Year 1.70
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.31 +8.07%
on 10/15/24
56.20 -1.33%
on 10/31/24
+1.49 (+2.76%)
since 10/04/24
3-Month
46.22 +19.97%
on 08/08/24
56.20 -1.33%
on 10/31/24
+6.68 (+13.70%)
since 08/02/24
52-Week
39.35 +40.91%
on 07/05/24
56.20 -1.33%
on 10/31/24
+2.63 (+4.98%)
since 11/03/23

Most Recent Stories

More News
Option Volatility And Earnings Report For November 4 - 8

We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.

QCOM : 165.18 (-0.05%)
GILD : 89.84 (+0.37%)
FSLY : 7.09 (-1.53%)
MRNA : 53.54 (-2.00%)
AMZN : 195.78 (-1.09%)
PLTR : 41.41 (-1.22%)
BMY : 55.45 (+2.08%)
ANET : 394.88 (+0.18%)
AAPL : 222.01 (-0.40%)
SMCI : 26.03 (-0.08%)
MSTR : 222.99 (-2.93%)
ABNB : 136.87 (+0.30%)
Un-spooky Halloween: PCE, Jobless Claims Tame

Thursday, October 31, 2024Jobs Week trudges along this morning, with Friday morning’s big Employment Situation report now on the horizon. Behind this stands the 2024 General Election — which could...

AAPL : 222.01 (-0.40%)
INTC : 22.52 (-2.93%)
IP : 56.60 (+1.49%)
SIRI : 25.93 (-6.22%)
AMZN : 195.78 (-1.09%)
BMY : 55.45 (+2.08%)
Initial Claims Lower-Than-Expected

Economic & Earnings CommentaryJobs Week trudges along this morning, with Friday morning’s big Employment Situation report now on the horizon. Behind this stands the 2024 General Election — which could...

AAPL : 222.01 (-0.40%)
INTC : 22.52 (-2.93%)
IP : 56.60 (+1.49%)
SIRI : 25.93 (-6.22%)
AMZN : 195.78 (-1.09%)
BMY : 55.45 (+2.08%)
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript

BMY earnings call for the period ending September 30, 2024.

BMY : 55.45 (+2.08%)
1 Healthcare REIT to Snag Now for 5% Yield

This article highlights a standout healthcare REIT that offers investors a strong 5% dividend yield.

ARE : 112.99 (+1.92%)
$SPX : 5,712.69 (-0.28%)
HCA : 363.16 (+1.67%)
DOC : 21.99 (+0.05%)
BMY : 55.45 (+2.08%)
2 Promising Growth Stocks to Buy and Hold for a Decade or Longer

These two growth stocks could be great additions to a long-term buy-and-hold portfolio.

RNA : 44.82 (+7.05%)
$SPX : 5,712.69 (-0.28%)
LLY : 806.14 (-1.56%)
UBER : 73.25 (unch)
CART : 44.64 (-0.30%)
BMY : 55.45 (+2.08%)
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

CRBP : 18.31 (+8.22%)
$SPX : 5,712.69 (-0.28%)
NVO : 109.72 (-1.98%)
MRK : 101.87 (-0.01%)
LLY : 806.14 (-1.56%)
ABBV : 200.47 (-1.51%)
PFE : 27.76 (-1.17%)
XBI : 99.22 (-0.05%)
BMY : 55.45 (+2.08%)
Bristol-Myers Squibb's Quarterly Earnings Preview: What You Need to Know

Bristol-Myers Squibb is gearing up to release its third-quarter earnings at the end of this month, and analysts expect a double-digit profit dip.

XLV : 146.77 (-0.66%)
$SPX : 5,712.69 (-0.28%)
BMY : 55.45 (+2.08%)
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

JNJ : 158.24 (-1.18%)
BMY : 55.45 (+2.08%)
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?

Last week, Bristol Myers BMY obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo (nivolumab).The FDA approved Opdivo as a perioperative treatment regimen for adults...

MRK : 101.87 (-0.01%)
PFE : 27.76 (-1.17%)
BMY : 55.45 (+2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 57.49
2nd Resistance Point 56.63
1st Resistance Point 56.04
Last Price 55.45
1st Support Level 54.59
2nd Support Level 53.73
3rd Support Level 53.14

See More

52-Week High 56.20
Last Price 55.45
Fibonacci 61.8% 49.76
Fibonacci 50% 47.78
Fibonacci 38.2% 45.79
52-Week Low 39.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar